Recognizing and Staging the Severity of NASH: What Tools Do We Have?

This program will include a discussion of off-label and investigational devices, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

What Is NASH?

Prevalence of NAFLD Growing in Parallel With Obesity and Metabolic Syndrome

Prevalence of NASH

Prevalence of NASH (cont)

Assessing Patients After NAFLD Diagnosis Factors to Identify When Considering Liver Biopsy

Initial Patient Assessment for Liver Biopsy

Biochemical Markers in NAFLD

Noninvasive Imaging Vibration-Controlled Transient Elastography

VCTE and AST/ALT Ratio

Noninvasive Imaging Interpretation VCTE, CAP, and ALT/AST

Who Is Not a Candidate for Liver Biopsy?

Review of Biomarkers for NAFLD/NASH

Future of Imaging for Patients With NAFLD MR

MRE

MRI-PDFF

Multiparametric MR

Next Steps: Imaging or Biopsy?

Key Takeaways

Key Takeaways (cont)

Abbreviations

Abbreviations (cont)